BRAF and melanoma: Statistical comparison of genes identified in treatment-naïve and vemurafenib-resistant melanomas revealed eight candidate tumor drivers enriched in treatment-resistant tumors: three known mediators of vemurafenib resistance (Braf , Mitf , and Cdkn2a) and five novel candidate genes (75).